Patents by Inventor Jorge Victor Gavilondo Cowley
Jorge Victor Gavilondo Cowley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390369Abstract: Chimeric antigen comprising multimeric aggregates of the extracellular domain of the programmed death ligand 1 (PD-L1) with a reduced binding capacity to the PD-1 and CD80 receptors as compared to the native PD-L1 molecule. The invention further discloses pharmaceutical compositions including said chimeric antigen and at least a pharmaceutically acceptable vaccine adjuvant. The chimeric antigen is used for the manufacturing of a drug to treat cancer or its metastases. The invention also discloses a method of treating cancer or its metastases in a subject in need thereof, characterized by the administration of a therapeutically effective amount of the pharmaceutical composition comprising the chimeric antigen described herein.Type: ApplicationFiled: September 28, 2021Publication date: December 7, 2023Inventors: Yanelys MORERA DIAZ, Javier SÁNCHEZ RAMÍREZ, Camila CANAÁN-HADEN AYALA, Monica BEQUET ROMERO, Marta AYALA ÁVILA, Isabel GONZALEZ MOYA, Sonia GONZALEZ BLANCO, Miladys LIMONTA FERNÁNDEZ, Luis Ariel ESPINOSA RODRÍGUEZ, Vladimir Armando BESADA PÉREZ, Jorge Victor GAVILONDO COWLEY
-
Publication number: 20230046501Abstract: Polypeptides comprising functional mutants of an isoform of the human vascular endothelial growth factor A (VEGF-A) folded in a non-natural re-arrangement, where the second and fourth cysteine of the mutant's polypeptide chain is only forming intramolecular bridges, while the seventh and eight are only part of intermolecular bonds. The invention further comprises antigenic preparations containing at least one of these polypeptides, and the pharmaceutical compositions comprising such antigenic preparations and vaccine adjuvants. The antigenic preparations according to the invention are used in the manufacturing of a drug, for the treatment of diseases related to the increment of angiogenesis, inflammation, and immunosuppression, as well as for the restoration of the immune system.Type: ApplicationFiled: December 21, 2020Publication date: February 16, 2023Inventors: Monica BEQUET ROMERO, Yanelys MORERA DIAZ, Marta AYALA ÁVILA, Jorge Victor GAVILONDO COWLEY, Javier SÁNCHEZ RAMÍREZ, Francisco HERNÁNDEZ BERNAL, Sonia GONZALEZ BLANCO, Luis Ariel ESPINOSA RODRÍGUEZ, Vladimir Armando BESADA PÉREZ, Mariela PÉREZ DE LA IGLESIA, Lian TRIMIÑO LORENZO, Miladys LIMONTA FERNÁNDEZ, Raimundo UBIETA GÓMEZ
-
Patent number: 9505830Abstract: The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with an increase in vasculature, such as age-related macular degeneration, cancer, and others.Type: GrantFiled: December 26, 2011Date of Patent: November 29, 2016Assignees: Centro de Ingenieria Genetica y Biotechnologia, Biorec S.A.Inventors: Humberto Lamdan Ordas, Jorge Victor Gavilondo Cowley, Marta Ayala Avila, Yasmiana Muñoz Pozo, Amaury Pupo Meriño, Gertrudis Rojas Dorantes, Lincidio Perez Sanchez
-
Patent number: 8883724Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: GrantFiled: November 4, 2009Date of Patent: November 11, 2014Assignee: Centro de Ingenieria Genética y BiotecnologiaInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Publication number: 20140086829Abstract: The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others.Type: ApplicationFiled: December 26, 2011Publication date: March 27, 2014Applicants: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Humberto Lamdan Ordas, Jorge Victor Gavilondo Cowley, Marta Ayala Avila, Yasmiana Munoz Pozo, Amaury Pupo Merino, Gertrudis Rojas Dorantes, Lincidio Perez Sanchez
-
Patent number: 8076297Abstract: The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.Type: GrantFiled: July 5, 2005Date of Patent: December 13, 2011Assignee: Centro De Ingenieria Genetica Y BiotecnologiaInventors: Maria del Carmen Abrahantes Pérez, Jesús Reyes González, Gloria Véliz Rios, Eduardo Martinez Diaz, Caridad Anais Gasmuri González, José Garcia Suárez, Mónica Bequet Romero, Luis Javier González López, Lila Rosa Castellanos Serra, Manuel Selman-Housein Sosa, Raúl Gómez Riera, Jorge Victor Gavilondo Cowley
-
Publication number: 20110218138Abstract: The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.Type: ApplicationFiled: July 5, 2005Publication date: September 8, 2011Inventors: María Del Carmen Abrahantes Pérez, Jesús Reyes González, Gloria Véliz Rios, Eduardo Martínez Díaz, Caridad Anais Gasmuri González, José Garcia Suárez, Mónica Bequet Romero, Luis Javier González López, Lisa Rosa Castellanos Serra, Manuel Selman-Housein Sosa, Raúl Gómez Riera, Jorge Victor Gavilondo Cowley
-
Publication number: 20100151566Abstract: The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo. These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model.Type: ApplicationFiled: October 30, 2007Publication date: June 17, 2010Inventors: Humberto Lamdan Ordás, Jorge Víctor Gavilondo Cowley, Marta Ayala Avila, Gertrudis Rojas Dorantes, Yanelys Morera Díaz, Osmany Guirola Cruz, Glay Chinea Santiago, Nelson Francisco Santiago Vispo
-
Publication number: 20100047265Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: ApplicationFiled: November 4, 2009Publication date: February 25, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Publication number: 20090312190Abstract: The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.Type: ApplicationFiled: November 21, 2006Publication date: December 17, 2009Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Jorge Victor Gavilondo Cowley, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Jeovanis Gil Valdés, Aída Zulueta Morales, Lisset Hermida Cruz, Marta Ayala Avila, Diamilé Gonzáles Roche, Rolando Paez Meireles, Patricia Gabriela Toledo Mayora, Mónica Sarria Núnez, Alexis Musacchio Lasa, Yuliet Mazola Reyes
-
Patent number: 7556809Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: GrantFiled: April 11, 2003Date of Patent: July 7, 2009Assignee: Centro De Ingenieria Genetica Y BiotechnologiaInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vázquez Blomquist
-
Publication number: 20080254050Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: ApplicationFiled: April 17, 2007Publication date: October 16, 2008Inventors: Monica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernandez Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vazquez Blomquist
-
Patent number: 6891023Abstract: Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.Type: GrantFiled: November 16, 2000Date of Patent: May 10, 2005Assignee: Centro Inmunologia MolecularInventors: Cristina Maria Mateo de Acosta Del Rio, Lourdes Tatiana Roque Navarro, Alejo Morales Morales, Rolando Pérez Rodríguez, Marta Ayala Ávila, Jorge Victor Gavilondo Cowley, Marta Dueñas Porto, Hanssel Bell García, Enrique Rengifo Calzado, Normando Iznaga Escobar, Mayra Ramos Zuzarte